Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A financials
$469.28−0.26%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $3.44B |
| Gross profit | $1.58B |
| Gross margin | 45.9% |
| Operating income | $68.2M |
| Net income | -$22.5M |
| Net margin | −0.7% |
| Diluted EPS | $-0.15 |
| EBITDA | $385.0M |
| Operating cash flow | $134.1M |
| Free cash flow | $13.9M |
| Diluted shares | 151.8M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $298.8M |
| Short-term investments | $0.00 |
| Total debt | $1.87B |
| Total assets | $6.24B |
| Total liabilities | $3.73B |
| Shareholders' equity | $2.47B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology